Chemomab Therapeutics Ltd.

CMMBHealthcare · BiotechnologyVisit siteCIK 0001534248

Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.): $9.9M
Price: $1.37
% Change (Daily % change from the live per-ticker quote feed.): -2.14%
Volume: 10.0K

About

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

Quick stats

Shares outstanding7.2M

Computed float6.8M

Float / shares94.1%

Cash runway (months)7.4

Key info

SectorHealthcare

IndustryBiotechnology

CIK0001534248

Websitehttps://www.chemomab.com

AI Summary

AI-generated

1/5

1mo ago

minorneutralother

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Chemomab Therapeutics announced that CEO Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference, available via webcast starting September 11, 2026.

Dr. Mor and Dr. Reg Seeto, CEO of merger partner Scipher Medicine, will co-host 1x1 investor meetings during the conference, with the definitive merger agreement announced in July expected to close before year-end.

Scipher plans to advance Chemomab's anti-CCL24 antibody nebokitug into a Phase 2 trial for rheumatoid arthritis, targeting a $24 billion market opportunity.